Addressing the high cost of prescription drugs continues to be a top health care priority for the public. On October 1, the U.S. Trade Representative (USTR) announced a proposed agreement with Canada and Mexico to revise the North American Free Trade Agreement (NAFTA). The trade agreement–now called the U.S.-Mexico-Canada Free Trade Agreement (USMCA)–will decrease competition from more affordable generic and biosimilar medicines and keep patients paying high drug prices for longer.
A recent poll shows that nearly 3 in 4 voters are concerned that changes to U.S. law to comply with USMCA would negatively impact drug prices, access to generic drugs and time for generic entry into the market. View the results in the infographic below.